Bureau Veritas Continues to Build Capabilities in the Energy and Renewables Sector Through the Acquisition of Versatec Energy B.V.
Bureau Veritas, a global leader in Testing, Inspection, and Certification services, today announced the acquisition ofVersatec Energy B.V., an independent and specialized technical advisory company for the offshore and onshore energy industry. This acquisition is in line with the LEAP | 28 strategy to create a new stronghold in the fast-growing renewables segment, underscoring the Group’s commitment to the energy transition, and strengthening its position as a crucial player in shaping a sustainable and safe energy sector.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241111646650/en/
Hinda Gharbi, CEO Bureau Veritas (Photo: Business Wire)
Bureau Veritas contributes to accelerating the energy transition by providing customers across the energy sector with end-to-end solutions to meet the immediate and future challenges of developing and operating renewables and other innovative low carbon assets. The acquisition of Versatec Energy B.V. is a strategic move strengthening Bureau Veritas' position as a key partner in ensuring technical compliance and mitigating industrial risks in the energy sector. This acquisition enables Bureau Veritas to expand its service offering in crucial areas including oil & gas, nuclear, renewables, particularly offshore wind, as well as low carbon energy such as hydrogen, its derivatives & carbon capture, utilization & storage (CCUS).
Versatec Energy B.V. is a specialized technical consultancy with a special focus on the offshore energy industry. It capitalizes on over 40 years of expertise in five core areas: health, safety & environment; operational excellence, quality & technical compliance, technical documentation & training, as well as digitalsmart solutions. Versatec Energy B.V. experts have developed valuable methodologies in the areas of Commissioning & Start-up, Asset Due Diligence, Operational Assurance & Readiness and Project Management. Headquartered in the Netherlands, the company employs 35 highly skilled experts and consultants and delivered revenues of €4.2 million in 2023. Since its inception, Versatec Energy B.V. has assisted over 1,500 global projects in Europe, Asia Pacific, the Middle East and Africa.
Hinda Gharbi, Chief Executive Officer of Bureau Veritas, comments: “The acquisition of Versatec Energy B.V. expands our capabilities in the renewables and energy sectors with a proven track record in asset due diligence, commissioning, start-up and project management, and a special focus on the offshore energy industry. Their expertise will help build our new stronghold in the sector. I warmly welcome all new colleagues from Versatec Energy to our company.”
Klaas-Otto Ykema, CEO of Versatec Energy, adds: “Having spent two decades in and around Offshore Energy, I have always admired Bureau Veritas’ diverse skills across testing, inspection and certification. Joining forces will allow to further expand a business with scale, ambition and a global client book thanks to our unique skills and talents developed over the last 40 years across all parts of the energy sector.”
***
About Bureau Veritas
Bureau Veritas is a world leader in inspection, certification, and laboratory testing services with a powerful purpose: to shape a world of trust by ensuring responsible progress.
With a vision to be the preferred partner for its customers’ excellence and sustainability, the company innovates to help them navigate change.
Created in 1828, Bureau Veritas’ 83,000 employees deliver services in 140 countries. The company’s technical experts support customers to address challenges in quality, health and safety, environmental protection, and sustainability.
Bureau Veritas is listed on Euronext Paris and belongs to the CAC 40 ESG, CAC Next 20, SBF 120 indices and is part of the CAC SBT 1.5° index. Compartment A, ISIN code FR 0006174348, stock symbol: BVI.
For more information, visit www.bureauveritas.com, and follow us on LinkedIn.
About Versatec Energy B.V.
Versatec Energy is a global technical consultancy company serving the Energy Industry ranging from Renewables, Offshore Wind & Carbon Capture Storage & Utilization (CCSU). Food & Pharma, Marine, Power, Petrochemical to the Oil & Gas Industries. For more than 40 years Versatec has provided expertise in all phases of a facility lifecycle. Versatec’s flexible, innovative solutions aim to reduce project and operational risks, as well as reduce operational cost. Versatec helps in mitigating industrial risks and offers technical expertise to projects worldwide in the areas of Process Technical Safety, Operational Excellence and Smart Data Software Solutions and aims to be the Partner in Technical Compliance for its clients.
For more information, visit https://versatec.nl/, and follow us on Linkedin.
Our information is certified with blockchain technology.
Check that this press release is genuine at www.wiztrust.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241111646650/en/
Contacts
ANALYST/INVESTOR CONTACTS
Laurent Brunelle
+33 (0)1 55 24 76 09
laurent.brunelle@bureauveritas.com
Colin Verbrugghe
+33 (0)1 55 24 77 80
colin.verbrugghe@bureauveritas.com
Karine Ansart
+33 (0)1 55 24 76 19
karine.ansart@bureauveritas.com
MEDIA CONTACTS
Anette Rey
+33 (0)6 69 79 84 88
anette.rey@bureauveritas.com
Martin Bovo
+33 (0)6 14 46 79 94
martin.bovo@bureauveritas.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Nemluvio ® (Nemolizumab) for Patients with Moderate-to-Severe Atopic Dermatitis13.12.2024 23:09:00 CET | Press Release
Galderma (SWX:GALD) today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Nemluvio® (nemolizumab) for the treatment of patients 12 years and older with moderate-to-severe atopic dermatitis, in combination with topical corticosteroids (TCS) and/or calcineurin inhibitors (TCI) when the disease is not adequately controlled with topical prescription therapies. This follows the recent U.S. FDA approval of Nemluvio for subcutaneous injection for the treatment of adults with prurigo nodularis in August 2024.12 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241213562840/en/ Atopic dermatitis affects more than 230 million people worldwide, impacting approximately 7% of people in the U.S.2-4 Often reported as one of patients’ most problematic symptoms, 87% of people with atopic dermatitis say they are seeking freedom from itch, with speed of itch relief therefore also prioritized by both patient
Experian’s 2024 Global Identity & Fraud Report Spotlights Huge Growth in Highly Personalized GenAI-Driven Fraud Attacks13.12.2024 15:00:00 CET | Press Release
Today, Experian announced its 2024 Global Identity & Fraud Report that provides a comprehensive view of the consumer and business response to the latest fraud patterns and fraud‑mitigation strategies in the worldwide financial services sector. The report offers combined insights from more than 1,000 businesses and fraud leaders globally, as well as 4,000 consumers, focusing on fraud management and the digital experience. Among its key insights, the report casts a bright spotlight on three factors driving the fast-evolving fraud landscape: the huge growth in Generative Artificial Intelligence (GenAI) technologies, changing government regulations, and the push among businesses to provide consumers with secure and convenient digital experiences. In response to these factors, the report’s findings revealed that businesses intend to increase fraud budgets driven by investments in AI and machine learning technologies. “Unlike other issues facing financial services companies, fraud operates b
Capcom Announces Onimusha Way of the Sword , Marking the First New Title in the Series in Over 20 Years! Work on an Okami Sequel Project Begins!13.12.2024 14:00:00 CET | Press Release
Capcom Co., Ltd. (TOKYO:9697) today announced that Onimusha Way of the Sword, the first new title in the Onimusha series in over 20 years, is scheduled to be released, while work on an Okami sequel project has also started. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241213232085/en/ Onimusha Way of the Sword (Graphic: Business Wire) The Onimusha series consists of swordplay action games where players assume the role of warriors with the superhuman powers of the Oni and fight against monsters bent on world domination. Onimusha Way of the Sword, scheduled to be released globally in 2026, is a Japanese-inspired dark fantasy game set at the beginning of the Edo period in Kyoto, which has been eerily transformed by clouds of Malice. In the game, the samurai protagonist is equipped with the Oni Gauntlet and engages in epic sword battles with the grotesque and otherworldly creatures known as Genma. Capcom hopes that players loo
BrightPath Bio and Cellistic Announces Process Development and Manufacturing Collaboration for Phase 1 Clinical Trial of iPSC-derived BCMA CAR-iNKT cell13.12.2024 13:51:00 CET | Press Release
BrightPath Bio (Tokyo Stock Exchange Growth 4594, “BrightPath”), a pioneer in iPS cell-derived Natural Killer T (“NKT”) cell therapy, and Cellistic, a leader in advanced iPS cell therapy manufacturing, today announced a process development and manufacturing agreement to advance BrightPath’s novel allogeneic CAR-T cell therapy platform, utilizing iPSC-derived NKT cells for clinical trials. The strategic collaboration includes the use of Cellistic's innovative 3D bioreactor-based manufacturing platform, Echo, to enable GMP-compliant, clinical-scale manufacturing of iPSC-derived BCMA-targeting CAR-NKT cells for Phase 1 multiple myeloma trial; establishing BrightPath as a first mover in this emerging field. “The use of NKT cells as effectors in allogeneic CAR-T therapy represents a promising strategy, offering not only direct cytotoxicity but also indirect anti-tumor activity through the priming of host CD8+ T cells—a mechanism expected to evade host immune rejection and to enhance the dur
CHMP Recommends Approval of Galderma’s Nemolizumab for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis in the European Union13.12.2024 07:00:00 CET | Press Release
Galderma today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting the marketing authorization of nemolizumab for the treatment of both atopic dermatitis and prurigo nodularis in the European Union (EU). The CHMP has recommended nemolizumab’s approval for subcutaneous use for the treatment of moderate-to-severe atopic dermatitis in patients aged 12 years and older who are candidates for systemic therapy, and for subcutaneous use for the treatment of adults with moderate-to-severe prurigo nodularis who are candidates for systemic therapy. This follows its approval for the treatment of adults with prurigo nodularis by the United States (U.S.) Food and Drug Administration (FDA) in August 2024.14 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241212936857/en/ Atopic dermatitis is a common, chronic, and flaring infl
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom